Last reviewed · How we verify
Aldomet (METHYLDOPA)
Aldomet (METHYLDOPA) is a small molecule drug developed by Merck, targeting Lysine-specific demethylase 4E. It belongs to the methyldopa class and was FDA-approved in 1962 for the treatment of hypertensive disorders. As an off-patent medication, Aldomet is available from multiple generic manufacturers. Key safety considerations include its potential for side effects such as drowsiness and liver damage. Aldomet has a half-life of 5.9 hours and bioavailability of 42%.
At a glance
| Generic name | METHYLDOPA |
|---|---|
| Sponsor | Merck |
| Drug class | methyldopa |
| Target | Lysine-specific demethylase 4E |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1962 |
Approved indications
- Hypertensive disorder
Common side effects
- Orthostatic hypotension
- Congestive heart failure
- Prolonged carotoid sinus hypersensitivity
- Edema or weight gain
- Bradycardia
- Pancreatitis
- Colitis
- Vomiting
- Diarrhea
- Sialadenitis
- Sore or black tongue
- Nausea
Key clinical trials
- [18F]F-DOPA Imaging in Patients With Autonomic Failure (PHASE1)
- Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease (PHASE3)
- A Study to Assess Effect of Dosing Intervals on Multiple-Dose Pharmacokinetics of WD-1603 Taken Before Meals in Healthy Participants (PHASE1)
- Dopaminergic Dysfunction in Late-Life Depression (PHASE2)
- Evaluation of sFlt-1/PlGF Ratio ,OPG and sEng as Predictive Biomarkers in the Diagnosis and Treatment Evaluation of Preeclampsia
- Effect of Pilates Exercise Versus Circuit Exercise Training on Gestational Hypertension (NA)
- Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Supplemental Open-Label Arm (PHASE1,PHASE2)
- Effects of 5HTP on the Injured Human Spinal Cord (PHASE2,PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aldomet CI brief — competitive landscape report
- Aldomet updates RSS · CI watch RSS